Digital Library
Close Browse articles from a journal
 
Search for with title:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Journal description
       All volumes of the corresponding journal
         All issues of the corresponding volume
                                       All articles of the corresponding issues
 
                             147 results found
no title author magazine year volume issue page(s) type
1 Author index 2005
 11 S2 p. 273-280
8 p.
 article
2 Committees 2005
 11 S2 p. viii-x
nvt p.
 article
3 ES159 A2 antagonists 2005
 11 S2 p. 98-
1 p.
 article
4 ES135 ADHD, Obsessive compulsive disorders & Tourette syndrome 2005
 11 S2 p. 94-
1 p.
 article
5 ES128 Antiglutamatergic compounds 2005
 11 S2 p. 91-
1 p.
 article
6 ES137 Antipsychotic treatment 2005
 11 S2 p. 94-
1 p.
 article
7 ES117 Atypical Parkinson's disease and tauopathies (PSP, CBDG, FTD-P) 2005
 11 S2 p. 88-89
2 p.
 article
8 ES130 Autonomic nervous system (vagaldysfunction) 2005
 11 S2 p. 92-
1 p.
 article
9 ES108 Basic aspects of tauopathies/synucleopathies 2005
 11 S2 p. 86-87
2 p.
 article
10 ES112 Biomarkers for the early diagnosis ofParkinson's disease 2005
 11 S2 p. 87-
1 p.
 article
11 ES118 Cholinomimetics 2005
 11 S2 p. 89-
1 p.
 article
12 ES110 Clinimetry of cognition and behavior in Parkinson's disease 2005
 11 S2 p. 87-
1 p.
 article
13 ES104 Deep brain stimulation (complications) 2005
 11 S2 p. 85-
1 p.
 article
14 ES145 Degenerative ataxias 2005
 11 S2 p. 97-
1 p.
 article
15 ES142 Drug study design 2005
 11 S2 p. 96-
1 p.
 article
16 ES113 Early onset Parkinsonism (Parkin,DJ-1 and PINK-1) 2005
 11 S2 p. 88-
1 p.
 article
17 ES120 Economics and disease related groups (DRG) 2005
 11 S2 p. 89-
1 p.
 article
18 ES121 Epidemiology 2005
 11 S2 p. 90-
1 p.
 article
19 ES133 Ethics 2005
 11 S2 p. 93-
1 p.
 article
20 ES143 Examination of specific cognitivedisturbances in Parkinson's disease patients 2005
 11 S2 p. 96-
1 p.
 article
21 ES131 Functional neuroanatomy 2005
 11 S2 p. 92-93
2 p.
 article
22 ES158 GAIT disorders 2005
 11 S2 p. 97-98
2 p.
 article
23 ES144 Gastrointestinal dysfunction inParkinson's disease 2005
 11 S2 p. 96-
1 p.
 article
24 ES119 Gene therapy 2005
 11 S2 p. 89-
1 p.
 article
25 ES106 Genomics & proteomics (methodology) 2005
 11 S2 p. 86-
1 p.
 article
26 ES132 Haw to use the UPDRS and quality oflife scales 2005
 11 S2 p. 93-
1 p.
 article
27 ES157 How to cope with complications ofadvanced Parkinson's disease and algorithms approach 2005
 11 S2 p. 97-
1 p.
 article
28 ES123 Lewy body: Is it toxic orneuroprotective? 2005
 11 S2 p. 90-
1 p.
 article
29 ES107 Multiple system atrophy 2005
 11 S2 p. 86-
1 p.
 article
30 ES139 Natural compounds 2005
 11 S2 p. 95-
1 p.
 article
31 ES115 Neuroimaging (SPECT/MRI) 2005
 11 S2 p. 88-
1 p.
 article
32 ES125 Neuroimaging (SPECT, PET) 2005
 11 S2 p. 90-
1 p.
 article
33 ES156 Neurophysiological investigations in movement disorders 2005
 11 S2 p. 97-
1 p.
 article
34 ES124 Neurophysiology (EEG, ERP, MEG,TMS, direct current stimulation) 2005
 11 S2 p. 90-
1 p.
 article
35 ES138 (non) Motor response fluctuations 2005
 11 S2 p. 95-
1 p.
 article
36 ES127 Olfaction (basic aspects, clinics) 2005
 11 S2 p. 91-
1 p.
 article
37 ES101 Overview on current dopaminomimeticmedication 2005
 11 S2 p. 84-
1 p.
 article
38 ES102 Parkinson's disease related depression (treatment) 2005
 11 S2 p. 84-85
2 p.
 article
39 ES129 Psychological treatment (coping with the disease, sexual dysfunction and communication) 2005
 11 S2 p. 91-
1 p.
 article
40 ES126 Restless legs & RBD 2005
 11 S2 p. 90-91
2 p.
 article
41 ES134 Single neuroprotective drug or a cocktail? 2005
 11 S2 p. 93-
1 p.
 article
42 ES105 Sleep and Parkinson's disease 2005
 11 S2 p. 85-
1 p.
 article
43 ES103 Stem cells (differentiation, (methodology) 2005
 11 S2 p. 85-
1 p.
 article
44 ES141 The effects of dance and live music on Parkinson's disease: Performance by Mark Morris Dance Group artists and pianist 2005
 11 S2 p. 95-96
2 p.
 article
45 ES136 Visual assessment (basic aspects,clinics) 2005
 11 S2 p. 94-
1 p.
 article
46 HT001 Hat topics: Treatment 2005
 11 S2 p. 77-
1 p.
 article
47 HT005 Hat topics: Treatment 2005
 11 S2 p. 81-82
2 p.
 article
48 HT002 Hot topics: Basal gangliapharmacology 2005
 11 S2 p. 78-
1 p.
 article
49 HT006 Hot topics: Genetics 2005
 11 S2 p. 82-83
2 p.
 article
50 HT004 Hot topics: STN Stimulation 2005
 11 S2 p. 80-
1 p.
 article
51 HT003 Hot topics: Varia 2005
 11 S2 p. 78-79
2 p.
 article
52 IS010 A novel botulinum toxin A product(Merz Pharma GmbH & Co. KGaA) 2005
 11 S2 p. 266-268
3 p.
 article
53 IS012 Continuous dopaminergic stimulation: New pharmacological approaches (NeuroBiotec GmbH/Axxonis Pharma) 2005
 11 S2 p. 269-270
2 p.
 article
54 IS011 Deep brain stimulation: the role of theneurologist for optimal patient benefits (Medtronic Inc.) 2005
 11 S2 p. 268-269
2 p.
 article
55 IS013 Dopamine agonists in clinical practice:Parkinson's disease treatment today and tomorrow (GlaxoSmithKline GmbH and Co KG) 2005
 11 S2 p. 270-
1 p.
 article
56 IS006 Dopamine transporter imaging — Challenging the evidence (GE Healthcare Ltd.) 2005
 11 S2 p. 265-
1 p.
 article
57 IS008 Exploring the role of adenosine A2Areceptors in the pathophysiology and treatment of Parkinson's disease (Kyowa Hakko Kogyo Co., LTD) 2005
 11 S2 p. 266-
1 p.
 article
58 IS001 Levodopa: the gold standard (NovartisPharma AG/Orion Corporation Orion Pharma) 2005
 11 S2 p. 261-
1 p.
 article
59 IS004 Rasagiline — A new and promising Parkinson's disease therapeutic approach (Lundbeck GmbH) 2005
 11 S2 p. 263-
1 p.
 article
60 IS005 Spheramine: A promisinginvestigational cell therapy far the treatment of Parkinson's disease (Schering AG/Titan Pharmaceuticals) 2005
 11 S2 p. 264-265
2 p.
 article
61 IS002 Subcutaneous apomorphine therapy inParkinson's disease — Recognising and overcoming the barriers (Britannia/Cephalon GmbH Germany) 2005
 11 S2 p. 261-263
3 p.
 article
62 IS003 The rotigotine patch: unique benefits forParkinsons disease patients (Schwarz Pharma AG) 2005
 11 S2 p. 263-
1 p.
 article
63 IS007 The scientific and clinical basisfar future therapies in Parlduson's disease (Boehringer Ingelheim GmbH & Co. KG) 2005
 11 S2 p. 265-266
2 p.
 article
64 IS009 Time to act: understanding restlesslegs syndrome (GlaxoSmithKline GmbH and Co KG) 2005
 11 S2 p. 266-
1 p.
 article
65 Medical historical exhibition 2005
 11 S2 p. 271-
1 p.
 article
66 [No title] 2005
 11 S2 p. 100-
1 p.
 article
67 [No title] 2005
 11 S2 p. 101-102
2 p.
 article
68 PL001 Pathophysiology 2005
 11 S2 p. 53-
1 p.
 article
69 PL003 Preclinical neuroprotection in Parkinson's disease 2005
 11 S2 p. 54-55
2 p.
 article
70 PL002 Presidental plenary lecture 2005
 11 S2 p. 53-54
2 p.
 article
71 PL004 Treatment strategies 2005
 11 S2 p. 55-57
3 p.
 article
72 PS004 Botulinum toxin 2005
 11 S2 p. 105-106
2 p.
 article
73 PS003 Cannabis and cannabinoids in Parkinson's disease and movement disorder 2005
 11 S2 p. 104-105
2 p.
 article
74 PS002 Rotigotine 2005
 11 S2 p. 103-104
2 p.
 article
75 PT008 Animal models and Parkinson's disease 2005
 11 S2 p. 136-140
5 p.
 article
76 PT022 Antidyskinetic drugs in animal models 2005
 11 S2 p. 181-183
3 p.
 article
77 PT014 Assessment of disease progression 2005
 11 S2 p. 154-158
5 p.
 article
78 PT032 Assessment of motor disturbances 2005
 11 S2 p. 217-221
5 p.
 article
79 PT044 Autonomic disturbances 2005
 11 S2 p. 258-260
3 p.
 article
80 PT002 Basic science: In vitro studies 2005
 11 S2 p. 108-111
4 p.
 article
81 PT015 Basic science: In viva studies 2005
 11 S2 p. 158-161
4 p.
 article
82 PT018 Cognitive disturbances 2005
 11 S2 p. 169-173
5 p.
 article
83 PT003 Deep brain stimulation I 2005
 11 S2 p. 111-116
6 p.
 article
84 PT027 Deep brain stimulation II 2005
 11 S2 p. 195-200
6 p.
 article
85 PT011 Depresion/sleep/pain 2005
 11 S2 p. 144-147
4 p.
 article
86 PT004 Dystonia and botulinum toxin 2005
 11 S2 p. 116-122
7 p.
 article
87 PT009 Economics 2005
 11 S2 p. 140-142
3 p.
 article
88 PT010 Etiopathogenesis 2005
 11 S2 p. 142-144
3 p.
 article
89 PT021 Etiopathogenesis - Environmental toxins 2005
 11 S2 p. 178-180
3 p.
 article
90 PT038 Etiopathogenesis — Metabolic disturbances 2005
 11 S2 p. 235-238
4 p.
 article
91 PT020 Experimental models — Cell cultures 2005
 11 S2 p. 177-178
2 p.
 article
92 PT025 Experimental models: Protein aggregation 2005
 11 S2 p. 188-192
5 p.
 article
93 PT030 Movement disorders 2005
 11 S2 p. 210-214
5 p.
 article
94 PT005 Movement disorders I 2005
 11 S2 p. 122-126
5 p.
 article
95 PT028 MSA and Ataxia 2005
 11 S2 p. 201-205
5 p.
 article
96 PT043 Neurogenetics 2005
 11 S2 p. 254-258
5 p.
 article
97 PT033 Neuroimaging 2 (MRI, TCS) 2005
 11 S2 p. 221-224
4 p.
 article
98 PT036 Neuroimaging 3 (PET) 2005
 11 S2 p. 228-230
3 p.
 article
99 PT013 Neuroimaging (SPECT) 2005
 11 S2 p. 150-154
5 p.
 article
100 PT001 Neuromelanin 2005
 11 S2 p. 107-108
2 p.
 article
101 PT040 Neurophysiology of movementdisorders 2005
 11 S2 p. 242-247
6 p.
 article
102 PT026 Neuroprotection in parkinsoniananimal models 2005
 11 S2 p. 192-195
4 p.
 article
103 PT037 Neurotoxin-induced movementdisorders 2005
 11 S2 p. 230-235
6 p.
 article
104 PT041 Non-pharmacological treatment of Parkinson's disease 2005
 11 S2 p. 247-250
4 p.
 article
105 PT031 Pharmacological treatment: Dopamineagonists, Duo Dopa 2005
 11 S2 p. 214-217
4 p.
 article
106 PT007 Pharmacological treatment: Dopaminergics 2005
 11 S2 p. 131-136
6 p.
 article
107 PT006 Pharmacological treatment: MAO-S inhibitors, COMT-inhibitors 2005
 11 S2 p. 126-131
6 p.
 article
108 PT024 Pharmacological treatment: Varia 2005
 11 S2 p. 185-187
3 p.
 article
109 PT023 Phenotype and genetics: Park 1-2 2005
 11 S2 p. 183-185
3 p.
 article
110 PT042 Phenotype and genetics: Park 3–8 2005
 11 S2 p. 250-254
5 p.
 article
111 PT017 Postmortem studies 2005
 11 S2 p. 165-169
5 p.
 article
112 PT039 Preclinical pharmacology: in vitra 2005
 11 S2 p. 239-242
4 p.
 article
113 PT019 Preclinical pharmacology: In vivo 2005
 11 S2 p. 173-176
4 p.
 article
114 PT016 Quality of life 2005
 11 S2 p. 161-165
5 p.
 article
115 PT035 Transgenic models of movementdisorders 2005
 11 S2 p. 226-228
3 p.
 article
116 PT034 Treatment of non-motor symptoms 2005
 11 S2 p. 224-226
3 p.
 article
117 PT029 Tremor and restless legs syndrome 2005
 11 S2 p. 205-210
6 p.
 article
118 PT012 Wilson's disease 2005
 11 S2 p. 147-149
3 p.
 article
119 S013 Clinical aspects of neuroprotection 2005
 11 S2 p. 70-71
2 p.
 article
120 S014 Controversies on new animal models of Parkinson's disease: Pro and con 2005
 11 S2 p. 71-
1 p.
 article
121 S005 Development of midbrain dopaminergicneurons 2005
 11 S2 p. 63-64
2 p.
 article
122 S004 Dystonia 2005
 11 S2 p. 62-
1 p.
 article
123 S008 Functional neuroanatomy 2005
 11 S2 p. 66-67
2 p.
 article
124 S003 Melvin Yahr Memorial Symposium 2005
 11 S2 p. 60-61
2 p.
 article
125 S019 New pharmacological treatment - Latest trials 2005
 11 S2 p. 75-
1 p.
 article
126 S006 Non-motor manifestations 2005
 11 S2 p. 64-
1 p.
 article
127 S016 Non-motor manifestations and earlydiagnosis 2005
 11 S2 p. 72-73
2 p.
 article
128 S017 Parkinson-plus disorders: Diagnosis and treatment — State of the Art (SWEMODIS) 2005
 11 S2 p. 73-74
2 p.
 article
129 S007 Pathology, what's new? 2005
 11 S2 p. 64-65
2 p.
 article
130 S009 Pathophysiology — what's new 2005
 11 S2 p. 67-68
2 p.
 article
131 S010 Progress in familial Parkinson's disease 2005
 11 S2 p. 68-
1 p.
 article
132 S012 Progress in PARK 8 2005
 11 S2 p. 69-70
2 p.
 article
133 S020 Role of P450 system in the CNS: implications for Parkinson's disease 2005
 11 S2 p. 75-76
2 p.
 article
134 S018 Surgical interventions 2005
 11 S2 p. 74-75
2 p.
 article
135 S011 The role of iron in neurodegeneration 2005
 11 S2 p. 68-69
2 p.
 article
136 S001 The significance of neuromelanin in the human brain — Symposium 1: Structural and functional characterization of neuromelanin 2005
 11 S2 p. 58-59
2 p.
 article
137 S002 The significance of neuromelanin in the human brain — Symposium 2: The role of neuromelanin in the pathogenesis of Parkinson's disease 2005
 11 S2 p. 59-60
2 p.
 article
138 S015 Transcranial brain sonography inneurodegenerative diseases 2005
 11 S2 p. 72-
1 p.
 article
139 V148-1 Dystonia 2005
 11 S2 p. 99-
1 p.
 article
140 V148-2 Dystonia (repeat) 2005
 11 S2 p. 99-
1 p.
 article
141 V149-1 Psychogenic and psychiatric movement disorders 2005
 11 S2 p. 99-
1 p.
 article
142 V149-2 Psychogenic and psychiatric movement disorders (repeat) 2005
 11 S2 p. 99-
1 p.
 article
143 V147-1 Tics, chorea, myoclonus 2005
 11 S2 p. 99-
1 p.
 article
144 V147-2 Tics, chorea, myoclonus (repeat) 2005
 11 S2 p. 99-
1 p.
 article
145 V146-1 Tremor 2005
 11 S2 p. 99-
1 p.
 article
146 V146-2 Tremor (repeat) 2005
 11 S2 p. 99-
1 p.
 article
147 Welcome addresses 2005
 11 S2 p. xi-xii
nvt p.
 article
                             147 results found
 
 Koninklijke Bibliotheek - National Library of the Netherlands